Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15714467 | 0.92 | MAPT (1.00) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL15714466 | 0.83 | MYC (1.00) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL15714452 | 0.82 | MAPT (0.82) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL15714458 | 0.80 | MAPT (0.74) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL245147 | 0.79 | MAPT (0.68) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL245490 | 0.77 | MAPT (0.68) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL245472 | 0.75 | MAPT (0.70) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL246344 | 0.74 | MAPT (0.67) | MYCMAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL9763027 | 0.74 | MEN1 (0.81) | MAPTALDH1A1KDM4EALOX15ALOX12 | |
| SCHEMBL14865047 | 0.72 | MAPT (1.00) | MAPTALDH1A1KDM4EALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917203-B1 | METHOD FOR IDENTIFYING MYC INHIBITORS | DANA FARBER CANCER INST INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567301-B2 | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-9540320-B2 | — | — | 2017-01-10 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2015-10-15 | — | — | US | disclosed |
| WO-2014071247-A1 | PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291521-A1 | PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS | MYC, MYCBP, YAP1 | MYC 1/4885MAPT 2353/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.